Abstract: Disclosed is cold-adapted live attenuated severe acute respiratory syndrome coronavirus (SARS-CoV-2) prepared by infecting cells with severe acute respiratory syndrome coronavirus and then adapting the severe acute respiratory syndrome coronavirus to a temperature from 37° C. to 22° C. in a step by step manner. Further, a vaccine containing the cold-adapted live attenuated severe acute respiratory syndrome coronavirus (SARS-CoV-2) is disclosed.

Abstract: The present invention relates to a novel compound isolated from Kaempferia pandurata Roxb and the use thereof as an antiviral agent. The compound isolated from Kaempferia pandurata Roxb shows the ability to inhibit highly pathogenic virus, and thus is a promising candidate for an antiviral agent.

Abstract: The present invention relates to a novel compound isolated from Allium tuberosum and the use thereof as an antiviral agent. The compound isolated from Allium tuberosum shows the ability to inhibit highly pathogenic virus, and thus is a promising candidate for an antiviral agent.

Abstract: The present invention relates to a novel lung epithelial cell line, preferably a porcine lung epithelial cell line, supporting efficient high titer replication of viruses, in particular, influenza viruses. In contrast to embryonated chicken eggs and known cell culture systems for influenza replication, propagation of influenza viruses in the lung epithelial cell line of the invention is not accompanied by antigenic changes in the HA1 region of the hemagglutinin molecule and is free of contaminants which are potentially harmful for vaccine production. The cell line of the invention is useful in virus surveillance, in studies of viral pathogenesis, and in the production anti-viral vaccines for humans and animals.